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One Sentence Summary: Cotrimoxazole reduces systemic and intestinal inflammation in 
HIV infection by suppressing gut-resident Streptococci and immune cell activation. 
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ABSTRACT 
Long-term cotrimoxazole prophylaxis reduces mortality and morbidity in HIV infection but the 
mechanisms underlying these sustained clinical benefits are unclear. Here we investigate the 
impact of cotrimoxazole on systemic inflammation, an independent driver of HIV mortality. We 
show that plasma inflammatory markers were lower in HIV-positive Ugandan and Zimbabwean 
children receiving antiretroviral therapy after randomization to continue (n=144) versus stop 
(n=149) cotrimoxazole. This was not explained by clinical illness, HIV progression or nutritional 
status. Since sub-clinical enteropathogen carriage and enteropathy can drive systemic 
inflammation, we explored the impact of cotrimoxazole on the gut microbiome and biomarkers 
of intestinal inflammation. Although global microbiome community composition was 
unchanged, viridans group Streptococci and streptococcal mevalonate pathway enzymes were 
lower among children who continued (n=36) versus stopped (n=36) cotrimoxazole. These 
changes were associated with lower fecal myeloperoxidase. To isolate direct effects of 
cotrimoxazole on immune activation from its antibiotic properties, we established in vitro 
models of systemic and intestinal inflammation. In vitro cotrimoxazole treatment had modest but 
consistent inhibitory effects on pro-inflammatory cytokine production by blood leukocytes from 
HIV-positive (n=16) and HIV-negative (n=8) U.K. adults. It also reduced IL-8 production by 
inflamed gut epithelial cell lines. Together, these data demonstrate that cotrimoxazole reduces 
systemic and intestinal inflammation both indirectly via antibiotic effects on the microbiome, 
and directly by blunting immune and epithelial cell activation. Synergy between these pathways 
may explain the clinical benefits of cotrimoxazole despite high antimicrobial resistance,  
providing further rationale for extending coverage among people living with HIV in sub-Saharan 
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Africa.
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INTRODUCTION 
In 2017, 36.9 million people were living with HIV and 940,000 died from AIDS-related 
illnesses(1). To reduce mortality and morbidity(2, 3), World Health Organization (WHO) 
guidelines recommend long-term cotrimoxazole prophylaxis for all people living with HIV in 
areas with a high prevalence of malaria and/or severe bacterial infections(4). However, it is 
unclear how cotrimoxazole reduces mortality and morbidity, given the high rates of 
antimicrobial resistance and selection for resistant pathogens with long-term use(2). There is 
therefore a need to better understand the effect of cotrimoxazole on HIV pathogenesis. 
 
Systemic inflammation is independently associated with mortality in HIV infection(5-7). 
Cotrimoxazole might plausibly confer benefits by reducing inflammation, either indirectly by 
targeting pathogens, or directly by modulating cells that produce pro-inflammatory 
mediators. Animal models suggest that antibiotics confer anti-inflammatory benefits(8), and 
observational studies of HIV-positive adults suggest that cotrimoxazole can reduce plasma 
inflammatory biomarkers(9, 10). Data from randomized trials and low-income settings are 
lacking and no studies have evaluated the effects of cotrimoxazole on pro-inflammatory 
pathways in HIV-positive individuals. 
 
HIV drives a chronic enteropathy, characterized by loss of villous architecture, increased gut 
permeability, mucosal CD4+ T cell depletion(11), leukocyte infiltration(12-14), and 
microbial translocation(15, 16), accompanied by increased pathogen carriage and an altered 
microbiome(17, 18); together, these changes contribute to systemic inflammation.  
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Cotrimoxazole prophylaxis could influence intestinal inflammation through antibiotic effects 
on enteropathogens and/or the microbiome, or via direct effects on mucosal leukocytes and 
gut epithelial cells(19, 20). Among HIV-positive Ugandan adults cotrimoxazole had limited 
effects on the gut microbiome(21), however the effects of cotrimoxazole have not been 
assessed in a randomized trial or in children.  
 
Cotrimoxazole comprises two folate pathway inhibitors, trimethoprim and sulfamethoxazole. 
The hypothesis that cotrimoxazole can directly inhibit pro-inflammatory immune cell 
activation was first posited in 1970, following the observation that intramuscular 
trimethoprim prolonged skin graft retention in mice(22). However, subsequent in vitro 
studies of the direct effects of cotrimoxazole on immune cells have yielded conflicting 
results(23-26) and none have assessed its anti-inflammatory effects in HIV-positive 
individuals. Cotrimoxazole treatment of rats impacts absorption across the gut 
epithelium(19), suggesting cotrimoxazole may influence gut barrier function, a critical 
regulator of cross-talk between the circulation and gut-resident microorganisms. 
 
Thus, cotrimoxazole prophylaxis confers long-term clinical benefits in HIV infection, which 
are not entirely explained by its antibiotic effects(2, 3). Inconsistent evidence suggests that 
cotrimoxazole may have anti-inflammatory properties, but conclusive data are lacking. We 
therefore capitalized on a randomized trial of continuing versus stopping cotrimoxazole in 
HIV-positive children in sub-Saharan Africa, to test the hypothesis that cotrimoxazole 
reduces systemic inflammation. We then explored mechanistic pathways through which 
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this may occur, using clinical data, stored specimens and in vitro models.  
  
 
      Submitted Manuscript:  Confidential             template updated: February 28 20 
Cotrimoxazole reduces systemic inflammation in HIV infection by altering 
the gut microbiome and immune activation  
8 
 
 
RESULTS 
Cotrimoxazole reduces systemic inflammation in HIV-positive children 
We have previously shown that randomization to continue versus stop cotrimoxazole 
prophylaxis reduced hospitalization or death among HIV-positive children on long-term 
antiretroviral therapy (ART) in the ARROW trial in Uganda and Zimbabwe(27). Since the 
inflammatory biomarkers C-reactive protein (CRP) and interleukin (IL-) 6 were 
independently associated with mortality in ARROW(5), we hypothesized that the benefits of 
cotrimoxazole might be partly mediated through reductions in systemic inflammation. CRP, 
IL-6, soluble (s)CD14, and tumor necrosis factor (TNF)α) were quantified in longitudinal 
plasma samples from children randomized to continue (n=144) versus stop (n=149) 
cotrimoxazole (Fig. 1).  
 
Biomarkers were similar between groups at baseline (Fig. 1A-D), but subsequent CRP 
concentrations from week-24 until the end of follow-up were lower in children randomized to 
continue cotrimoxazole (global p: 0.006; Fig. 1A). IL-6 was also significantly lower among 
children continuing cotrimoxazole, particularly at early timepoints (Global p: 0.010; week-12 
p: 0.014, week-24 p: 0.003; Fig. 1B). There was no evidence of global differences between 
groups in sCD14 (Fig. 1C) or TNFα (Fig. 1D). Serum albumin was significantly higher 
(median: 42 versus 41g/L, p=0.041) and total protein significantly lower (76 versus 78g/L, 
p=0.038) in children continuing cotrimoxazole at week-48 (Fig. 1E), consistent with less 
systemic inflammation. Collectively these results show that cotrimoxazole reduces systemic 
inflammation in HIV-positive children. 
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To estimate the clinical implications of these findings, we used relative risk estimates of 
adverse outcomes (death, new or recurrent WHO clinical stage 4 events, or poor 
immunological response to ART) associated with baseline (i.e. pre-ART) concentrations of 
CRP and IL-6 in ARROW(5). Stopping cotrimoxazole led to 1.65-fold higher CRP (stop, 
2.71mg/L versus continue, 1.64mg/L; Fig. 1A) and 1.18-fold higher IL-6 (stop, 5.36pg/mL 
versus continue, 4.54pg/mL; Fig. 1B) at week-24, corresponding to an increased relative risk 
of adverse clinical outcomes among children stopping cotrimoxazole of 13% (95% CI: 4-
24%) and 11% (95% CI: 4-18%), respectively, within 24 weeks(5). Relative differences in 
CRP peaked at week-48 (1.92-fold increase; stop, 2.86mg/L versus continue, 1.49mg/L; Fig. 
1A), corresponding to an 18% (95% CI: 6-32%) increased risk of adverse clinical outcomes. 
Thus, differences in CRP and IL-6 with continued cotrimoxazole are important for long-term 
survival, health and immune restoration among HIV-positive children. 
 
Reduced systemic inflammation is not solely due to less clinical disease 
Lower systemic inflammation with long-term cotrimoxazole could be due to reductions in 
HIV disease progression or clinical illness(2, 27). However, there was no evidence of global 
differences in the proportion of children with viral suppression (<80 HIV RNA copies/mL; 
Fig. 2A) or in CD4+ T cell percentages (%CD4; Fig. 2B) between randomized groups. There 
was also no evidence for global differences in caregiver-reported cough (Fig. 2C), fever (Fig. 
2D), nausea/vomiting (Fig. 2E) or abdominal pain (Fig. 2F). Too few children had persistent, 
bloody or moderate-to-severe diarrhea, difficult/fast breathing and/or weight loss for 
comparison between groups. HIV-positive children frequently have malnutrition; antibiotics 
(including cotrimoxazole) have been shown to improve growth(28) and slow weight-loss(29).  
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We therefore compared anthropometry between randomized groups, reasoning that 
differences in systemic inflammation might be explained by underlying wasting or stunting. 
We found no evidence of differences in weight-for-age (Fig. 2G) or height-for-age Z-scores 
(Fig. 2H). Thus, effects of cotrimoxazole on systemic inflammation were not explained by 
differences in HIV disease progression, symptomatic infections or malnutrition between 
groups.  
 
Cotrimoxazole alters circulating CD4+ T cell phenotypes in HIV-positive children  
Although cotrimoxazole continuation had no impact on total CD4+ T cell counts, we 
hypothesized that CD4+ T cell phenotypes would differ between randomized groups because 
systemic inflammation is associated with T cell activation and proliferation(30, 31) (5). T cell 
immunophenotyping in a subset of Ugandan ARROW participants (stop n=48, continue 
n=47; fig. S1A) revealed no evidence of differences between randomized groups in the 
proportions of total CD4+ T cells expressing the activation marker HLA-DR or the 
proliferation marker Ki67 (fig. S1B and C). Children continuing cotrimoxazole had higher 
percentages of recent thymic emigrant-like cells (RTE, CD4+CD45RA+CD31+ T cells; an 
indicator of thymic output(32)) than children stopping prophylaxis (fig. S1B). There was no 
evidence of differences in proportions of naïve (CD4+CD45RA+CD31-) or effector-memory 
(CD4+CD45RA-CD31-) T cells or in the expression of HLA-DR on any CD4+ T cell sub-
populations (fig. S1C). However, children continuing cotrimoxazole had lower percentages 
of proliferating (Ki67+) RTE and naïve T cells, particularly at later timepoints post-
randomization (fig. S1D). Thus, cotrimoxazole continuation led to some changes in 
circulating T cells consistent with reduced systemic inflammation(5). 
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Cotrimoxazole suppresses abundance and function of gut-resident Streptococci  
The gut microbiome is disrupted by HIV infection, which contributes to local and systemic 
inflammation(17, 33). We hypothesized that continuing cotrimoxazole would drive sustained 
sub-clinical differences in gut pathogens and commensals. We conducted whole metagenome 
shotgun sequencing of total fecal DNA from children randomized to continue (n=36 at week-
84; n=33 at week-96) versus stop cotrimoxazole (n=36 at week-84; n=35 at week-96). 
Randomized groups did not differ in species-level diversity at week-84 or week-96 (Shannon 
indices: 13.1 continue versus 14.3 stop, p=0.27; and 13.5 continue versus 14.8 stop, p=0.72) 
or evenness (Pileou’s index: 0.59 continue versus 0.60 stop, p=0.605; and 0.60 continue 
versus 0.61 stop, p=0.883). Bacterial community composition was also similar between 
groups (Fig. 3A and B) . However, false discovery rate (FDR)-adjusted zero-inflated beta 
regression analysis of individual microbiome characteristics identified 7 bacterial species 
(Alistipes onderdonkii, Eggerthella lenta, Clostridium bartlettii, Haemophilus 
parainfluenzae, Streptococcus mutans, Streptococcus parasanguinis and Streptococcus 
vestibularis; fig. S2) and 11 protein families (Pfam; fig. S3) mapping to Streptococcus 
parasanguinis, Streptococcus salivarius and Haemophilus parainfluenzae, that were 
consistently less abundant at both timepoints in the continue versus stop group (relative 
abundance ratio <1). The differentially abundant Streptococci are all within the viridans 
group (VGS), and largely fell in the quadrant of the NMDS ordination plot where the 
extremes of the treatment groups lay (Fig. 3A and B). The relative abundance of 
Enterobacteriaceae, which includes gastrointestinal pathogens (e.g. Salmonella, Escherichia 
coli, and Shigella) that are frequently resistant to cotrimoxazole(34, 35), was not affected by 
cotrimoxazole at week-84 (relative abundance ratio: 0.65, adjusted p=0.108) and was  
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increased in those continuing versus stopping cotrimoxazole at week-96 (4.48, adjusted 
p<0.001).  
 
To understand the effect of cotrimoxazole on microbiome function, we quantified the 
abundance of full sets of genes involved in metabolic pathways across bacterial taxa. Only 
mevalonate pathway I, which influences neutrophil and monocyte recruitment and function, 
was consistently different between groups at both timepoints. Mevalonate pathway-associated 
genes were significantly less abundant in stool samples from children continuing 
cotrimoxazole (week-84 adjusted p=0.042, and week-96 adjusted p=0.019; Fig. 3C). Of the 
enzyme-encoding genes within mevalonate pathway I, those with identity to Streptococcus 
parasanguinis (5 enzymes, KEGG EC: 1.1.1.88 (hydroxymethylglutaryl-CoA (HMG-CoA) 
reductase), 2.3.3.10 (HMG-CoA synthase), 2.7.1.36 (mevalonate kinase) and 4.1.1.33 
(diphosphomevalonate decarboxylase) and 5.3.3.2 (isopentenyl-diphosphate Delta-
isomerase); adjusted p<0.05 at both timepoints) and Streptococcus salivarius (2 enzymes, 
KEGG EC: 1.1.1.88 and 5.3.3.2; adjusted p<0.05 at both timepoints) were significantly less 
abundant in the continue group (Fig. 3C), suggesting that continuation of cotrimoxazole 
reduces VGS metabolic function in the gut. 
 
To confirm this metagenomic signature of VGS suppression by cotrimoxazole, we conducted 
high-resolution mapping of metagenome sequencing reads to Streptococci pangenome 
datasets using PanPhlAn software, which has a lower false-positive rate for species 
identification and better discrimination between samples containing the same versus different  
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bacterial genomes than MetaPhlAn(36). Of the 140 stool samples sequenced (both groups at 
week-84 and week-96), PanPhlAn identified 29 samples positive for any Streptococci (9 
species present: S. salivarius, S. parasanguinis, S. mutans, S. vestibularis, S. australis, S. 
infantarius, S. oligofermentans, S. pasteurianus, and S. sanguinis) and, of these, 20 samples 
positive for at least one of the 4 VGS species identified using MetaPhlAn (7 at week-84 and 
13 at week-96). PanPhlAn identified a lower percentage of VGS-positive samples on account 
of its higher species-level resolution (Fig. 3D and E). Six samples from children continuing 
and 14 samples from children stopping cotrimoxazole were confirmed VGS-positive across 
both timepoints, corroborating VGS suppression by cotrimoxazole. Individual VGS species 
were present less often in children continuing cotrimoxazole (Fig. 3E). Together, these 
findings show that continuing compared to stopping long-term cotrimoxazole does not affect 
global microbiome community composition, but does drive specific alterations in gut 
microbiome structure and function, with suppression of VGS and associated reductions in 
VGS mevalonate pathway genes.  
 
Cotrimoxazole-induced changes in Streptococci reduce intestinal inflammation  
We next tested whether these microbiome changes influenced HIV enteropathy. We 
compared levels of fecal inflammatory markers at week-84 and week-96 post-randomization 
to continue (n=37) or stop (n=38) cotrimoxazole. At week-84, fecal myeloperoxidase was 
significantly lower in children continuing versus stopping cotrimoxazole (median: 
1694ng/mL versus 3178ng/mL, p=0.022; Fig. 4A), but there was no evidence of differences 
in neopterin, alpha-1-antitrypsin, or REG1β between groups (p>0.15, fig. S4A). At week-96, 
myeloperoxidase did not significantly differ between randomized groups  (1262 versus  
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1473ng/mL, p=0.093; Fig. 4B) and there was no evidence of differences in neopterin, alpha-
1-antitrypsin or REG1β (p>0.15, fig. S4B). Since myeloperoxidase is an abundant peroxidase 
enzyme in monocytes and neutrophils that perpetuates granulocyte activation(37) and both 
cell types home to the gut mucosa during HIV infection(13, 14), these observations suggest 
that cotrimoxazole reduces innate immune cell activity in the gut. 
 
Of the bacterial species suppressed by cotrimoxazole, Streptococcus mutans, Streptococcus 
vestibularis, Streptococcus parasanguinis, and Haemophilus parainfluenzae were positively 
associated with myeloperoxidase levels at week-96 (Streptococcus spp. summarized in Fig. 
4C; analysis of all species in fig. S5), after adjustment for age, sex, and cotrimoxazole group. 
Myeloperoxidase was also positively associated with Pfam that were differentially abundant 
according to cotrimoxazole treatment: 5 with identity to Streptococcus parasanguinis, 2 to 
Streptococcus salivarius, 2 to Haemophilus parainfluenzae, and 1 to Eubacterium bioforme 
at week-96 (Pfam with identify to Streptococcus spp. summarized in Fig. 4C; analysis of all 
Pfam in fig. S6). Overall mevalonate pathway I abundance was significantly associated with 
higher myeloperoxidase at week-96 (adjusted p<0.001, Fig. 4C). Of the mevalonate pathway 
I enzymes that differed between randomized groups, only those with identity to 
Streptococcus parasanguinis (5 enzymes, adjusted p<0.001) and Streptococcus salivarius (2 
enzymes, adjusted p<0.01) had a significant positive association with myeloperoxidase (Fig. 
4C). We therefore show that all VGS components suppressed by cotrimoxazole (Fig. 3C) 
were positively associated with myeloperoxidase (Fig. 4C), suggesting that reduced VGS 
abundance and function contribute to lower intestinal inflammation among children 
continuing cotrimoxazole.  
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Cotrimoxazole blunts pro-inflammatory cytokine responses in vitro  
Having established that cotrimoxazole reduces both systemic and intestinal inflammation, we 
next investigated whether cotrimoxazole has direct immunomodulatory properties. To isolate 
any direct effects of cotrimoxazole on immune cells from its impact on enteropathy and the 
microbiome, we optimized an in vitro model of whole blood cytokine responses to bacterial 
and fungal antigens: heat-killed Salmonella typhimurium (HKST), which activates immune 
cells via Toll-like receptor (TLR) 2, 4 and 5; purified Escherichia coli lipopolysaccharide 
(LPS), which engages TLR4; and the Saccharomyces cerevisiae cell-wall component 
zymosan, which engages TLR2 and dectin-1. Antigens engaging pattern recognition receptors 
were chosen to reflect microbial translocation, which drives systemic inflammation and 
immune activation in HIV infection(7, 15, 18, 33). The cotrimoxazole dose was chosen to 
reflect maximum (high-dose; 8μg/mL trimethoprim and 200μg/mL sulfamethoxazole) and 
minimum (low-dose; 2μg/mL trimethoprim and 50μg/mL sulfamethoxazole) serum 
concentrations in HIV-positive patients taking cotrimoxazole(38). Laboratory cotrimoxazole 
preparations were confirmed to have antibiotic activity (fig. S7A) and doses did not reduce 
leukocyte viability in culture (fig. S7B-D). 
 
Since the inflammatory milieu can affect immune cell responses, we obtained blood samples 
from three groups of U.K. adults (HIV-positive ART-treated (n=6), HIV-positive ART-naïve 
(n=10) and HIV-negative (n=8), table S1), with distinct baseline inflammatory profiles (fig. 
S8). There was no difference between groups in spontaneous cytokine production in 24h 
unstimulated cultures (Fig. 5).  
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High-dose cotrimoxazole significantly reduced HKST-, LPS- and zymosan-induced TNFα 
(Fig 5A) and IL-6 (Fig 5B) production relative to control treatment with drug diluent alone 
(dimethyl sulfoxide, DMSO) in ≥1 group. This was particularly evident for HKST- and LPS-
induced TNFα and LPS- and zymosan-induced IL-6, which were significantly lower across 
all three clinical groups. LPS- and zymosan-induced TNFα and zymosan-induced IL-6 were 
also significantly reduced by low-dose cotrimoxazole in the HIV-positive ART-naïve group 
(Fig 5A and B). These observations confirm our hypothesis that cotrimoxazole directly 
modulates pro-inflammatory immune cell activation by pathogen antigens, both in HIV-
positive and in HIV-negative individuals, independently of its effects on the microbiome or 
intestinal inflammation. 
 
To determine the immune cell types modulated by cotrimoxazole, we evaluated intracellular 
TNFα production and surface expression of HLA-DR by monocytes and T cells during 6h 
PBMC culture with or without high-dose cotrimoxazole (gating strategy shown in fig. S9; 
antibodies in table S2). Cotrimoxazole reduced the proportion of TNFα+ monocytes after 
HKST stimulation relative to control-treated cultures in the HIV-negative group but not in the 
HIV-positive groups (Fig. 5C). Cotrimoxazole did not alter HKST-induced up-regulation of 
HLA-DR by monocytes (Fig. 5D). Cotrimoxazole also had no effect on the proportion of 
TNFα+ or HLA-DR+ CD4+ or CD8+ T cells after polyclonal stimulation with staphylococcal 
enterotoxin B (SEB; Fig. 5C and D). Thus, although cotrimoxazole reduces pro-
inflammatory cytokine production by blood leukocytes and TNFα production by monocytes 
specifically, it did not directly reduce monocyte maturation or T cell activation. 
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Cotrimoxazole reduces IL-8 production by gut epithelial cells 
The gut epithelium provides a barrier between the microbiota and mucosal immune cells, 
responds to TLR ligands, and produces leukocyte chemoattractants under inflammatory 
conditions; direct effects of cotrimoxazole on epithelial cell function could contribute to its 
anti-inflammatory effects. To isolate direct effects of cotrimoxazole on the epithelial barrier 
from its impact on leukocytes or the microbiome, we used transwell cultures of the Caco-2 
human colonic epithelial cell-line as a well-established model of gut epithelium. We induced 
epithelial inflammation with IL-1β and evaluated the effect of cotrimoxazole on four 
epithelial functions: epithelial integrity (trans-epithelial resistance, TEER), epithelial cell 
death (%Lactose dehydrogenase (LDH) activity), apical-to-basal translocation of a 
fluorescent dye (%Lucifer Yellow passage, a proxy for gut-to-circulation microbial 
translocation), and production of the neutrophil chemoattractant IL-8 (Fig. 6A). We used 
high cotrimoxazole concentrations for these experiments to reflect the concentration found in 
the gut lumen following oral dosing, after first titrating cotrimoxazole in Caco-2 cultures to 
identify a dose that did not differ in cytotoxicity from DMSO controls (1mg/mL; Fig. 6B).  
 
Cotrimoxazole treatment throughout Caco-2 growth did not significantly alter the rate of 
monolayer confluence (mean TEER/plate >800Ω; Fig. 6C), ΔTEER, %LDH activity or 
%Lucifer yellow passage under inflammatory conditions (1, 10, or 100μg/mL IL-1β for 24h; 
Fig. 6D). However, cotrimoxazole-treated monolayers produced significantly less IL-8 than 
control-treated cultures when the inflammatory stimulus was highest (100μg/mL IL-1β, 
p=0.003, Fig. 6D). Taken together, these experiments suggest that cotrimoxazole directly  
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inhibits IL-8 production by gut epithelial cells, which may contribute to reduced neutrophil 
recruitment to the intestinal mucosa under inflammatory conditions.   
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DISCUSSION 
Inflammation drives morbidity and mortality in HIV infection. There is therefore interest in 
using anti-inflammatory agents with ART to improve clinical outcomes(39-42). Long-term 
cotrimoxazole prophylaxis is recommended for children and adults living with HIV in 
settings with high prevalence of malaria or invasive bacterial infections, although global 
coverage remains poor(4, 43). We show here that cotrimoxazole reduces systemic 
inflammation in ART-treated children in sub-Saharan Africa, and demonstrate several 
underlying mechanisms, including antibiotic effects on the gut microbiome and direct anti-
inflammatory effects on leukocytes and gut epithelial cells. Synergy between antibiotic and 
anti-inflammatory pathways may explain the sustained clinical benefits of cotrimoxazole(3, 
27) and provides an additional rationale for increasing cotrimoxazole coverage in sub-
Saharan Africa.  
 
Using samples from the ARROW trial, we show definitively, using the randomized stop-
versus-continue design, that systemic inflammatory biomarkers (CRP and IL-6) are reduced 
by cotrimoxazole. . Pre-ART levels of CRP and IL-6, but not TNFα or sCD14, predicted 
mortality, WHO stage 4 clinical events, and poor CD4 reconstitution in ARROW; a 2-fold 
increase in CRP or IL-6 was independently associated with 19% and 54% increased risk, 
respectively(5). Based on these predictions, the reductions in CRP and IL-6 among children 
continuing cotrimoxazole would reduce the relative risk of adverse outcomes by 13% and 
11%, respectively. HIV-positive children have lower absolute mortality risk after starting 
ART; however, our estimates highlight that the additive anti-inflammatory benefits of  
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continuing cotrimoxazole are clinically meaningful. Previous studies suggest that Systemic 
inflammatory mediators are better predictors of poor clinical outcomes than T cell activation 
among HIV-positive people in resource-limited settings(44). Our assessment of circulating 
immune cell activation was limited to HLA-DR expression on CD4+ T cells, which did not 
differ between randomized groups.  However, we observed lower percentages of proliferating 
naïve CD4+ T cells among children continuing cotrimoxazole, which we interpret as 
beneficial, since elevated CD4+ T cell proliferation without a corresponding increase in total 
counts leads to depletion of the naïve T-cell pool(45).  
 
We went on to explore potential explanatory mechanisms. Systemic inflammation in HIV 
infection is partly driven by enteropathogen carriage and chronic enteropathy(11-13, 15). 
Using stool samples from a subset of ARROW children, we demonstrated that VGS were less 
abundant at week-84 and week-96 post-randomization in those continuing cotrimoxazole. 
Since speciation of VGS is challenging, we confirmed these differences using high-resolution 
mapping of metagenome sequencing reads to Streptococcal pangenomes databases(36). 
Cotrimoxazole effects on VGS are particularly striking because global microbiome 
community composition did not differ between randomized groups, likely because all 
children had received cotrimoxazole for median 2 years pre-randomization(27). VGS are a 
heterogeneous group of bacteria, which can be both commensal and pathogenic(46). They are 
found throughout the healthy human gut(47, 48) and are enriched in stool samples from 
children with stunting(49), a form of chronic malnutrition associated with systemic 
inflammation(50). VGS express several immune-stimulatory antigens that may drive 
intestinal inflammation, and potently trigger innate immune cell cytokine production in  
  
 
      Submitted Manuscript:  Confidential             template updated: February 28 20 
Cotrimoxazole reduces systemic inflammation in HIV infection by altering 
the gut microbiome and immune activation  
21 
 
 
vitro(51). In contrast to changes in VGS, we found no evidence for suppression of 
Enterobacteriaceae, which include pathogens causing severe bacterial infections in sub-
Saharan Africa(34, 35). Our microbiome analyses focused on later timepoints post-
randomization, due to stool sample availability; there may plausibly be additional 
cotrimoxazole-driven changes at earlier timepoints and at other anatomic sites. 
 
Children randomized to continue cotrimoxazole had lower fecal myeloperoxidase, an 
antimicrobial peroxidase enzyme abundant in neutrophils, and a biomarker of 
enteropathy(52). Of the cotrimoxazole-affected VGS, S. mutans, S. parasanguinis and S. 
vestibularis were positively associated with myeloperoxidase, suggesting that sub-clinical 
antibiotic effects of cotrimoxazole on VGS reduce intestinal inflammation. This does not 
appear to be a universal characteristic of antibiotic treatment since suppression of gut-resident 
gram-positive bacteria with vancomycin in rhesus macaques subsequently infected with SIV 
did not reduce IL-6 or CD4+ T cell activation in mesenteric lymph nodes(53). It is likely that 
timing of treatment, baseline microbiome, ART history, intercurrent infections, and antibiotic 
specificity influence the relationship between antibiotic prophylaxis, gut microbiome and 
enteropathy.  
 
Functional analysis of ARROW stool samples identified a metagenomic signature of 
mevalonate metabolism, predominantly mapping to VGS, which was positively associated 
with fecal myeloperoxidase and suppressed by cotrimoxazole. The mevalonate pathway is 
one of two metabolic processes that produce isoprenoids, naturally-occurring organic  
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precursors in eukaryote cholesterol and prokaryote cell wall peptidoglycan (a TLR2 ligand) 
synthesis (54). Several in vitro studies indicate that inhibition of mevalonate pathway 
enzymes impairs innate leukocyte recruitment and pro-inflammatory cytokine responses, 
providing a precedent for how inhibiting VGS mevalonate metabolism might influence HIV 
enteropathy. For example, inhibiting farnesyl pyrophosphate synthesis reduces neutrophil 
priming by IL-8(55), and inhibiting HMG-CoA reductase reduces monocyte IL-6 and IL-
8(56) and neutrophil trans-epithelial migration(39, 42). HMG-CoA reductase with identity to 
Streptococcus parasanguinis and Streptococcus salivarius was among the cotrimoxazole-
suppressed mevalonate pathway enzymes identified.  
 
Leukocytes are an abundant source of pro-inflammatory cytokines. Levels of circulating 
microbial products that could trigger these pathways are elevated during HIV infection, 
including the TLR4 ligand LPS(10, 15). We developed an in vitro model of leukocyte 
activation by TLR ligands to isolate direct anti-inflammatory effects of cotrimoxazole from 
its antibiotic effects, using blood samples from HIV-negative and HIV-positive U.K. adults 
not receiving cotrimoxazole. Although this cohort differed in age, geographic location, likely 
HIV clade and co-morbidities compared to children in ARROW, these in vitro experiments 
provide proof-of-concept that physiologically-relevant cotrimoxazole doses consistently 
inhibited whole blood TNFα and IL-6 production elicited via TLR2, 4 and 5. Collectively, 
these findings suggest that modulation of innate pro-inflammatory cytokine production is a 
property of cotrimoxazole per se, affects multiple innate signaling pathways, and occurs 
independently of its antibiotic effects, HIV-driven inflammation or ART exposure. 
Intracellular cytokine staining suggested that monocyte rather than T cell cytokine production  
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was most affected by cotrimoxazole. Our demonstration of direct modulation of pro-
inflammatory cytokine production by human leukocytes clarifies a longstanding theory that 
cotrimoxazole modulates immune responses in mice via an undefined mode-of-action(22), 
for which subsequent in vitro models have yielded opposing conclusions for innate and 
adaptive immune cells (23-26). Although these immunomodulatory effects were 
quantitatively subtle, our relative risk estimates in ARROW indicate that even small 
reductions in inflammatory markers may improve clinical outcomes(5). The pharmacology of 
cotrimoxazole-mediated immunosuppression, its interaction with TLR signaling and potential 
therapeutic value in other inflammatory disorders are yet to be established.  
 
Cotrimoxazole reduced production of the neutrophil chemoattractant IL-8 by gut epithelial 
cells in vitro. This is a putative pathway through which cotrimoxazole could directly 
contribute to reduced neutrophil recruitment and myeloperoxidase production in the gut 
mucosa. Cotrimoxazole did not alter epithelial characteristics associated with barrier function 
in vitro; however, it remains possible that cotrimoxazole alters these pathways in vivo by 
affecting gut barrier components such as mucus(19) and tight junction proteins(53), which we 
did not model. Primary epithelial cells and biopsies, which would better mimic trans-
epithelial transport in vivo, were not available from ARROW. Since VGS express abundant 
TLR2 ligands and Caco-2 have limited TLR2 expression(57), alternative epithelial models 
are required to explore inter-relationships between cotrimoxazole, VGS metabolism and 
epithelial barrier function. 
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Our study raises the possibility that antibiotics other than cotrimoxazole may confer anti-
inflammatory benefits that contribute to their impact at scale, including the recent finding of 
reduced child mortality following mass administration of azithromycin in sub-Saharan 
Africa(58). Accessory benefits from antibiotics are important considerations in the debate 
around antimicrobial stewardship, particularly in settings where antimicrobial resistance is 
already high and in conditions such as HIV, where chronic inflammation combines with 
intercurrent infection to exacerbate clinical outcomes. Whether cotrimoxazole has clinical 
benefits for HIV-positive people in high-income settings, where long-term cotrimoxazole 
prophylaxis is not currently recommended and ART alone does not fully prevent pathology, 
warrants further study. Recognition of its anti-inflammatory benefits should drive renewed 
efforts for universal cotrimoxazole coverage to improve clinical outcomes for all people 
living with HIV in sub-Saharan Africa.   
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MATERIALS & METHODS 
Study design 
 The study objective was to determine whether cotrimoxazole has anti-inflammatory effects, 
and to elucidate underlying mechanisms. Experimental work comprised: 1) analysis of 
longitudinal blood samples (using ELISA and flow cytometry) and stool samples (using 
ELISA and whole metagenome sequencing) collected from HIV-positive Ugandan and 
Zimbabwean children randomized to continue versus stop open-label cotrimoxazole in the 
ARROW trial(27), until 16th March 2012; and, 2) in vitro cotrimoxazole treatment using 
blood samples from U.K. adults (ELISA and flow cytometry) and epithelial cell-line (Caco-2) 
cultures. Full details are in Supplementary Materials and Methods. 
 
Within ARROW, children/adolescents (median age: 7.9 years, IQR: 4.6, 11.1) who had been 
receiving ART and once-daily cotrimoxazole prophylaxis (200mg of sulfamethoxazole and 
40mg of trimethoprim, 400mg sulfamethoxazole/80mg trimethoprim, or 800mg 
sulfamethoxazole/160mg trimethoprim for body weight 5-15, 15-30, or >30 kg, respectively) 
for >96 weeks at four sites in Uganda and Zimbabwe, were randomized to stop (n=382) or 
continue (n=386) cotrimoxazole(27, 59). Children with a history of Pneumocystis jirovecii 
pneumonia were excluded(27). 98% of children enrolled into ARROW during the last 6 
months of recruitment were also included in an immunology sub-study; additional assays 
were conducted for these children and for a random 23% sample of all remaining non-
immunology sub-study children (5). The current analysis included children with available 
baseline plasma of sufficient volume to measure inflammatory biomarkers (stop n=149,  
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continue n=144). Stool samples were collected at week-84 and week-96 post-randomization 
from a subgroup of children in Zimbabwe to assay intestinal inflammation. Total DNA was 
extracted from 150mg stool for whole metagenome sequencing (stop n=36, continue n=36). 
 
Blood was collected from 8 HIV-uninfected adults, 6 HIV-positive adults on ART for ≥2 
years, and 10 HIV-positive ART-naïve adults (table S1) who were not taking cotrimoxazole, 
for 24h whole blood culture and 6h PBMC culture with bacterial and fungal antigens. Pro-
inflammatory cytokine responses were compared between parallel cultures treated with 
cotrimoxazole and volume-matched diluent without drug (DMSO).   
 
Caco-2 monolayers were grown in transwell cultures as a gut epithelium model. Epithelial 
functions (integrity, cell death, translocation across the epithelium and chemokine 
production) were quantified after 24h stimulation with IL-1β and compared between cultures 
treated with cotrimoxazole or DMSO throughout growth, run in triplicate. Transwell cultures 
were repeated 3 times using separate Caco-2 passages. Data from individual transwells were 
excluded if monolayers were sub-confluent. 
 
Ethics 
ARROW (ISRCTN Registry# ISRCTN24791884) was approved by Research Ethics 
Committees in Uganda, Zimbabwe, and the U.K. Written informed consent from all 
caregivers and assent from participants (where appropriate) was obtained (27, 59). Approval 
for U.K. donor recruitment was provided by the National Health Service Research Authority  
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(IRAS project ID: 209553; Research Ethics Council reference: 17/WM/0018) and the 
Research Ethics Committee of Queen Mary University of London. All participants provided 
written informed consent. 
 
Statistical analysis 
For ARROW data, fold-change in geometric means between randomized groups were 
compared for continuous variables at each timepoint using standard regression models and 
globally across all timepoints using generalized estimating equations (GEE; normal 
distribution for log-transformed values), both with adjustment for recruitment center and 
baseline values, and assuming variation in treatment effect by timepoint. Proportions of 
children with HIV viral load <80 copies/mL were compared between randomized groups at 
each timepoint using Exact tests and globally across all timepoints using GEE (binomial 
distribution) with adjustment for recruitment center and assuming variation in treatment 
effect by timepoint. Relative risk projections for CRP and IL-6 differences between 
randomized groups were calculated from the output of models based on enrolment (i.e. pre-
ART and pre-cotrimoxazole) biomarker levels in the ARROW immunology sub-cohort (5). 
GEE and Exact tests were conducted in STATA version 15.1 (StataCorp LLC). 
Concentrations of fecal inflammatory markers and serum protein (Shapiro-Wilk test for 
normality, p<0.05) were compared between randomized groups using Mann-Whitney U test 
in Prism version 7.02 (GraphPad). 
                                                                                                                                                   
For microbiome sequencing data, differences in species relative abundance and diversity  
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between randomized groups were evaluated at each timepoint by intention-to-treat analysis 
using linear regression models fitted against natural log-transformed inverse Shannon 
species-level alpha-diversity indices. Species-level beta diversity was evaluated using the 
Bray–Curtis dissimilarity index, and visualized using NMDS. Differences in relative 
abundance of species, Pfam, metabolic pathways, and enzymes (microbiome characteristics) 
were evaluated at each time point by intention-to-treat analysis using separate zero-inflated 
beta regression models fitted against relative abundances for each microbiome characteristic. 
Cotrimoxazole treatment effect was the ratio of relative microbiome characteristic abundance 
in continue versus stop groups. P-values were adjusted for multiple comparisons to maintain 
the FDR significance level (α=0.05)(60). Only differentially abundant microbiome 
characteristics with consistent significant differences between groups at both week-84 and 
week-96 were interpreted as causally related to cotrimoxazole continuation. Rank-based 
regression models were fitted against fecal myeloperoxidase concentration adjusted for age, 
sex, and randomized group, with FDR adjustment for multiple comparisons. Microbiome 
analyses were conducted in R version 3.3.2. VEGAN(61) was used to calculate Shannon 
diversity, Bray-Curtis dissimilarity and NMDS. Gamlss was used for zero-inflated beta 
regression(62). Rfit was used for rank-based regression(63).  
 
For U.K. adults, continuous variables were compared between groups using unpaired 
Kruskall-Wallis tests. Comparisons between drug treatments were only conducted for 
responses that were significantly up-regulated in antigen-stimulated cultures without drug 
treatment versus un-stimulated cultures without drug treatment (paired Wilcoxon test, 
p<0.05). Comparisons between drug treatments used Freidman tests with post-hoc pair-wise  
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comparisons via uncorrected Dunn’s test; post-hoc tests were only conducted where the 
global test was statistically significant.  Caco-2 read-outs (TEER, ΔTEER, % LDH activity, 
% Lucifer Yellow passage, and IL-8; Shapiro-Wilk test for normality, p>0.05) were 
compared between cotrimoxazole-treated and DMSO-treated cultures using paired two-tailed 
t-tests. All analyses were conducted using Prism. 
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SUPPLEMENTAL MATERIALS 
Materials and Methods 
Figure S1. Cotrimoxazole alters circulating CD4+ T cell phenotype in HIV infection. 
Figure S2. Fecal bacterial species that differ between HIV-positive ART-treated 
Zimbabwean children randomized to continue versus stop cotrimoxazole prophylaxis.  
Figure S3. Protein families that differ between stool samples from HIV-positive ART-treated 
Zimbabwean children randomized to continue versus stop cotrimoxazole prophylaxis. 
Figure S4. Fecal biomarkers of enteropathy that were unaffected by continuing versus 
stopping cotrimoxazole prophylaxis. 
Figure S5. Associations between all fecal bacterial species that differed between HIV-positive 
children randomized to continue versus stop cotrimoxazole prophylaxis and fecal 
myeloperoxidase.  
Figure S6. Associations between all fecal Pfam that differed between HIV-positive children 
randomized to continue versus stop cotrimoxazole prophylaxis and fecal myeloperoxidase. 
Figure S7. Optimization of in vitro blood leukocyte activation and cotrimoxazole treatment 
conditions. 
Figure S8. HIV-positive adults have greater systemic inflammation, monocyte and T cell 
activation than HIV-negative adults. 
Figure S9. Flow cytometry gating strategy for analysis of monocyte and T cell intracellular 
cytokine responses. 
Table S1. Characteristics of HIV-negative and HIV-positive U.K. adult volunteers 
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Table S2. Details of fluorophore-conjugated antibody combinations used for flow cytometry 
analysis of PBMC from HIV-negative and HIV-positive adults. 
Data file S1. Primary data for in vitro cotrimoxazole treatment assays.
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Figure 1. Systemic inflammation is lower among HIV-positive children randomized to 
continue daily oral cotrimoxazole prophylaxis. Geometric mean concentrations of (A) 
CRP, (B) IL-6, (C) TNFα, and (D) sCD14 in plasma of HIV-positive children who had been 
receiving ART and cotrimoxazole for ≥96 weeks and were then randomized to stop (orange 
circles) or continue (green squares) cotrimoxazole. Randomized groups were compared 
across timepoints using generalized estimating equations and at individual timepoints using 
standard regression models (normal distribution for log-transformed values), adjusted for 
center and baseline concentrations (global p; A-D); *p<0.05, **p<0.01 ***p<0.001. (E) 
Serum protein concentrations at week-48 post-randomization; horizontal bars indicate means. 
Comparisons between groups by Mann-Whitney U test; *p<0.05, **p<0.01 ***p<0.001. 
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Figure 2. Cotrimoxazole effects on systemic inflammation are not solely due to 
differences in HIV disease progression, symptomatic infections, or nutritional status. 
(A) Percentage of children with viral load <80 copies/mL; (B) geometric mean percentage 
CD4+ T cells; mean proportions of children with caregiver-reported (C) cough, (D) fever, (E) 
vomiting/nausea and (F) abdominal pain; geometric mean (G) weight-for-age and (H) height-
for-age Z-scores in children randomized to continue versus stop cotrimoxazole prophylaxis (n 
per group shown under each graph). Randomized groups were compared by generalized 
estimating equations across timepoints (global p) and at individual timepoints using standard 
regression models (binomial distribution for viral load; normal distribution for log-
transformed values) adjusted for recruitment center; *p<0.05, **p<0.01 ***p<0.001.   
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Figure 3. Continuation of cotrimoxazole suppresses the abundance and function of 
viridans group Streptococci in stool samples from HIV-positive children. Non-metric 
multidimensional scaling plots of the Bray–Curtis dissimilarity index for stool samples from 
72 HIV-positive Zimbabwean children randomized to stop (orange) versus continue (green) 
cotrimoxazole at (A) week-84 and (B) week-96 post-randomization. Red crosses indicate 
individual bacterial species irrespective of randomized group; VGS species that consistently 
differed between randomized groups are labelled. Randomized groups were compared by  
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permutation tests. (C) Effect size plots of relative abundance ratios (±95% confidence 
interval) for all Streptococcus spp. and their protein families (Pfam) and mevalonate 
pathway-associated genes (KEGG EC), and metabolic pathways (all bacterial species) that  
significantly differed between randomized groups at both week-84 and week-96 in FDR-
adjusted zero-inflated beta regression. Identities for Pfam and KEGG EC were established 
using HUMANn2 against the UniRef90 database. Relative abundance ratio <1.0 indicates 
lower relative abundance in children who continued versus stopped cotrimoxazole. Vertical 
line indicates null value. Size of square is inversely proportional to p-value. Percentage of 
samples positive for any of the four VGS or individual species according to (D) MetaPhlAn 
and (E) PanPhlAn analysis at week-84 (continue n=36, stop n=36) and week-96 (continue 
n=33, stop n=35) 
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Figure 4. Intestinal inflammation in HIV-positive children is associated with gut-
resident viridans group Streptococci that are suppressed by continuation of 
cotrimoxazole. Myeloperoxidase at (A) week-84 and (B) week-96 in stool samples from 
HIV-positive Zimbabwean children randomized to stop versus continue cotrimoxazole.  
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Randomized groups compared by Mann-Whitney U test; *p<0.05, horizontal lines indicate 
median. (C) Effect size plots showing average change in myeloperoxidase per 1% change in 
relative abundance (±95% confidence interval) for all Streptococcus spp. and their protein 
families (Pfam) and mevalonate pathway-associated genes (KEGG EC), and metabolic 
pathways (all bacterial species) that significantly differed between randomized groups at both 
week-84 and week-96 in FDR-adjusted zero-inflated beta regression (Fig. 3C). Identities for 
Pfam and KEGG EC were established using HUMANn2 against the UniRef90 database. 
Average change >1.0 indicates increase in myeloperoxidase with increased abundance. 
Vertical line indicates null value. Size of square inversely proportional to p-value.  
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Figure 5. Cotrimoxazole inhibits in vitro pro-inflammatory cytokine responses to 
bacterial and fungal antigens. Tukey boxplots of (A) TNFα and (B) IL-6 concentrations in 
supernatants from whole blood cultures without antigen (No Stimulus), with heat-killed 
Salmonella typhimurium (HKST), lipopolysaccharide (LPS); or zymosan. Cultures were 
treated with low-dose cotrimoxazole (CTX[Low]: 2 μg/mL trimethoprim, 50 μg/mL 
sulfamethoxazole), high-dose cotrimoxazole (CTX[High]: 8 μg/mL trimethoprim, 200 μg/mL 
sulfamethoxazole) or volume-matched controls (DMSO[Low], DMSO[High]). Proportions of 
monocytes (left), CD4+ (center) and CD8+ T-cells (C) producing TNFα and (D) expressing 
HLA-DR after 6h PBMC culture with HKST or staphylococcal enterotoxin B (SEB). Grey 
bars indicate HIV-negative (n=8); red indicate HIV-positive ART-treated (n=6); and blue  
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indicate HIV-positive ART-naïve group (n=10). Cytokine concentrations in cotrimoxazole-
treated cultures are indicated by darker shading. Drug treatments compared within groups by  
Freidman tests with post-hoc uncorrected Dunn’s tests; *p<0.05, **p<0.01, ***p<0.001. 
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Figure 6. Cotrimoxazole reduces in vitro IL-8 production by gut epithelial cells under 
inflammatory conditions. (A) Light microscopy of confluent Caco-2 monolayer (200 μm 
scale bar) and diagram showing transwell culture model. (B) Percentage lactose 
dehydrogenase activity relative to lysed cells (%LDH) of Caco-2 cultured for 24h with 
titrated concentrations of cotrimoxazole (CTX; black bars) or volume-matched DMSO 
control (grey bars); %LDH compared to untreated controls and between volume-matched 
pairs of cotrimoxazole and DMSO by adjusted Tukey’s test; ***p<0.001. (C) Daily trans-
epithelial resistance (TEER) in transwell Caco-2 cultures without drug (white circles), 1 
mg/mL cotrimoxazole (black circles) or DMSO (grey circles) relative to transwells without 
Caco-2 (no cells; white triangles); mean ±SEM, n=3 separate experiments. Dotted line 
indicates culture confluence (TEER≥800Ω) . (D) Epithelial cell functions (Δ TEER, % LDH, 
% apical-to-basal passage of Lucifer Yellow dye relative to transwells without Caco-2 cells, 
and IL-8 concentration in apical supernatants) of confluent Caco-2 monolayers treated with 1 
mg/mL CTX or DMSO since seeding, then incubated with media alone (no stimulus) or IL-
1β for 24h; mean ±SEM, n=3 separate experiments. Cotrimoxazole and DMSO-treatment 
compared by 2-tailed t-tests; *p<0.05, **p<0.01 
